Activaero Cooperates with Bayer HealthCare in the Development of Inhaled Treatments.GEMUNDEN, Germany -- Activaero GmbH, the world leader in controlled breathing technologies for inhaled in·hale v. in·haled, in·hal·ing, in·hales v.tr. 1. To draw (air or smoke, for example) into the lungs by breathing; inspire. 2. therapeutic agents, today announced a licensing and option agreement with Bayer HealthCare AG on the development of inhaled treatments. Under the terms of the agreement, Activaero will receive an upfront payment and in case the option will be exerted subsequently milestone payments as well. Dr. Gerhard Scheuch, Founder and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Activaero commented: "This licensing deal represents a major milestone for Activaero and together with our scientific team, we look forward to supporting Bayer HealthCare throughout the upcoming development. We believe that pulmonary pulmonary /pul·mo·nary/ (pool´mo-nar?e) 1. pertaining to the lungs. 2. pertaining to the pulmonary artery. pul·mo·nar·y adj. Of, relating to, or affecting the lungs. administration of drugs has a huge potential for the treatment of lung diseases lung disease Pulmonary disease Pulmonology Any condition causing or indicating impaired lung function Types of LD Obstructive lung disease–↓ in air flow caused by a narrowing or blockage of airways–eg, asthma, emphysema, chronic bronchitis; and diseases which start in the lung. With this in mind, it will be exciting to develop innovative therapies with Bayer HealthCare, a world-wide leader in the pharmaceutical business for decades." Activaero is the world leader in controlled breathing technologies for inhaled therapeutic agents. With stand alone inhalation inhalation /in·ha·la·tion/ (in?hah-la´shun) 1. the drawing of air or other substances into the lungs.inhala´tional 2. the drawing of an aerosolized drug into the lungs with the breath. 3. products and inhalation systems available for clinical trials and marketing partnerships, Activaero's technologies allow for the most precise and efficient patient-tailored pulmonary delivery. Activaero currently has two products on the market, AKITA[R], a patient-tailored controlled breathing system with a smartcard that records the patient dosing parameters, and Watchhaler[TM], a hand held delivery system tailored specifically to children. The Company also has available a range of technologies ideal for the controlled delivery of inhaled therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. in the clinical trial setting and tailored to specific partnerships (AKITA2[R], LimiX[TM]). Finally, Activaero works with partners on a consultancy basis in the development of ideal inhaled delivery systems and the logistics in clinical trials. Activaero's technological approach has been validated repeatedly in the clinical setting. The Company is privately held and located in Gemunden (Wohra) and Munich in Germany and Dublin, Ohio Dublin is a city in Delaware, Franklin, and Union counties in the U.S. state of Ohio. The population was 31,392 at the 2000 census. In 2006, the population was estimated to be 36,565[1], and Dublin continues to be one of the fastest-growing suburbs of Columbus. in the USA. Activaero has been supported in the strategy, negotiation and process of this licensing transaction by Tytonis B.V. (www.tytonis.com) |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion